Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy

Immunotherapy has dramatically changed prognosis for patients with malignant tumors. However, as a non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDAC) has a low response to immunotherapy. Factors that contribute to the inefficiency of PDAC immunotherapy include the tumor microenvironment...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Wanting, Yang, Biao, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607590/
https://www.ncbi.nlm.nih.gov/pubmed/36297467
http://dx.doi.org/10.3390/pharmaceutics14102033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607590/
https://www.ncbi.nlm.nih.gov/pubmed/36297467
http://dx.doi.org/10.3390/pharmaceutics14102033

Ejemplares similares